TJ106 / Phrontline Biopharma - LARVOL DELTA

Preclinical development of TJ106, a potent biparatopic dual payload ADC targeting HER2 for the treatment of Enhertu-resistant tumors (AACR 2026) - "In vivo antitumor activity was investigated in cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models with high, moderate, or low HER2 expression. TJ106 consists of a biparotopic antibody, generated from trastuzumab and pertuzumab using knob-into-hole technology, conjugated in a site-specific manner (DAR 4) to the dual-linker payload DLP1, which combines a topoisomerase I inhibitor and a microtubule inhibitor. TJ106, a novel biparatopic dual-payload HER2-targeting ADC, demonstrates robust in vitro and in vivo antitumor activity, including in Enhertu-resistant models, supporting its further clinical development for patients with advanced HER2-expressing tumors."

ADC • Preclinical • Breast Cancer • Colorectal Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Oncology • Solid Tumor • HER-2

Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026 (The Manila Times) - "The data demonstrate robust antitumor activity across HER2-expressing tumor models, including those with low or heterogeneous HER2 expression and models resistant to prior HER2-targeted therapies and antibody-drug conjugates, including Trastuzumab deruxtecan....Phrontline plans to advance TJ106 into IND-enabling studies with an anticipated Investigational New Drug (IND) submission in early 2027. A global Phase I clinical trial is expected to evaluate TJ106 in patients with HER2-expressing solid tumors, including breast and gastric cancers, with a focus on patients previously treated with HER2-targeted therapies, including ADCs."

IND • Preclinical • Breast Cancer • Gastric Cancer • Solid Tumor